Physician profile
Amanda Nall
NPI 1184262511
$4,608.84
in general payments reported to CMS, 2019-2025
20 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,185 · 2022: $969 · 2023: $186 · 2024: $154 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314 · Travel and Lodging: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.89 |
| Travel and Lodging | $1,140.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,281.41 | 2021-2025 | Linq II, Micra, Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $492.75 | 2021-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $321.27 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.84 | 2021-2022 | |
| Pfizer INC. | $209.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $204.64 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $161.05 | 2021-2022 | |
| Abbott Laboratories | $130.75 | 2022-2025 | Cardiomems |
| Amgen INC. | $112.98 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.29 | 2021-2023 | Camzyos, Eliquis |
| Tactile Systems Technology INC | $76.08 | 2021 | |
| Merck Sharp & Dohme LLC | $71.95 | 2021-2022 | |
| Cvrx, INC. | $51.50 | 2022 | |
| Inari Medical, INC. | $45.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.95 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $26.54 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $22.55 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $20.24 | 2021 | |
| Amarin Pharma, INC. | $13.82 | 2021 | |
| Boston Scientific Corporation | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Nall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.